New technology for detecting cancer mutations in DNA
Official title: Development of An Innovative TEE Technology for Mutation Detection
Funded at Glc Biotechnology, INC. · NIH-10930942 · Data updated 2026-11-12
This study is testing a new way to extract DNA from blood and tumor samples to help doctors find cancer mutations more accurately, which could lead to better diagnosis and treatment for cancer patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Glc Biotechnology, INC. NIH-funded |
| Lab location | 1 site (Hudson, UNITED STATES) |
| Project start | September 18, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $928,164 |
| NIH project number | 5R44CA284965-02 |
| Project ID | NIH-10930942 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients who require mutation detection for personalized treatment plans.
✕Less likely to help
Patients without cancer or those whose conditions do not involve detectable mutations may not benefit from this research.
What this research studies
This research focuses on developing a novel DNA extraction method called Toehold-Enrichment-Extraction (TEE) to improve cancer detection and management. TEE allows for the extraction of mutated DNA with high recovery rates, enabling more sensitive testing than traditional methods. By using TEE, the research aims to enhance the accuracy of mutation detection tests, making it possible to identify mutations at much lower concentrations in clinical samples like blood and tumor tissues. This innovative approach could significantly improve the diagnostic capabilities for cancer patients.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate cancer diagnoses, improving treatment outcomes for patients.
How similar studies have gone: Previous research has shown promising results with similar DNA extraction technologies, indicating potential for success in this innovative approach.
Where this research is happening
-
Glc Biotechnology, INC.
Hudson, United States Active
Researchers
- Principal investigator: Deng, Qipan — Glc Biotechnology, INC.
- Study coordinator: Deng, Qipan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.